Application of lobaplatin in preparing medicines for treating malignant pleural mesothelioma

A malignant and pleural technology, applied in the application field of lobaplatin in the preparation of drugs for the treatment of malignant pleural mesothelioma, which can solve the problems of no treatment effect on malignant pleural mesothelioma

Inactive Publication Date: 2017-07-25
GUIZHOU YIBAI PHARMA CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although previous studies have shown that lobaplatin can be used to prepare and treat various diseases such as breast cancer, small cell lung cancer and chronic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lobaplatin in preparing medicines for treating malignant pleural mesothelioma
  • Application of lobaplatin in preparing medicines for treating malignant pleural mesothelioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: Study on the activity of lobaplatin against pleural mesothelioma in vitro

[0019] 1.1 Materials and reagents

[0020] 1.1.1 Drug name and source: Lobaplatin is white freeze-dried powder, Hainan Changan International Pharmaceutical Co., Ltd.; carboplatin is white powder, Kunming Guiyan Pharmaceutical Co., Ltd.; pemetrexed, Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd. ; Cisplatin is yellow powder, Jiangsu Hansoh Pharmaceutical Co., Ltd.

[0021] Preparation method: the above drugs are formulated with corresponding concentrations in serum-free medium.

[0022] 1.1.2 Cell lines

[0023] Pleural mesothelioma NCL-H2452 cells were purchased from the American Standard Biological Collection (ATCC) and cultured according to the instructions provided.

[0024] 1.1.3 Reagents and instruments

[0025] DMEM / F12 (1:1) medium, fetal bovine serum (Gibco, USA), penicillin (100,000 u / L), streptomycin (100 mg / L), CO 2 Incubator, ELx800 microplate reader (Bio-Tek, US...

example 2

[0042] Trial Example 2: In vivo curative effect study of lobaplatin on pleural mesothelioma

[0043] 2.1 Materials and reagents:

[0044] 2.1.1 Drug name and source: Lobaplatin is white freeze-dried powder, Hainan Changan International Pharmaceutical Co., Ltd.; carboplatin is white powder, Kunming Guiyan Pharmaceutical Co., Ltd.; pemetrexed, Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd. ; Cisplatin is yellow powder, Jiangsu Hansoh Pharmaceutical Co., Ltd.

[0045] 2.1.2 Experimental animals and cells

[0046] Clean-grade Kunming mice (4-6 weeks old) were provided by the Department of Animals, Kunming Medical College; pleural mesothelioma NCL-H2452 cells were purchased from the American Standard Biological Collection (ATCC).

[0047] 2.1.3 Reagents and instruments

[0048] DMEM / F12 (1:1) medium, fetal bovine serum (Gibco, USA), penicillin (100,000 u / L), streptomycin (100 mg / L), inverted microscope, CO 2 Incubator, pipette, suction ear ball, alcohol lamp.

[0049] 2.2...

Embodiment 3

[0066] Example 3: Clinical trials of lobaplatin in the treatment of pleural mesothelioma

[0067] 3.1 Case selection: According to the CT diagnosis of pleural mesothelioma in the literature (Liu Zhisong; Jing Suining; Wang Jianhong), the application of ultrasonography in the diagnosis of pleural mesothelioma (Shi Linshu; Yang Wenlan; Tao Juwei), thoracoscopy in the diagnosis of pleural mesothelioma Applications in diagnosis and treatment (Wang Yongliang) were screened according to UICC TNM staging. Screened out 19 patients with definite diagnosis of pleural mesothelioma, and all patients had KPS scores greater than 60. 19 patients were randomly divided into two groups, 10 cases in the treatment group, 5 males and 5 females, aged 50-64 years, with an average age of 58.6 years, 2 cases in stage III, 8 cases in stage IV; 9 cases in the control group, male 5 cases, 4 females, aged 52-60 years old, average 56.9 years old, 2 cases in stage III, 7 cases in stage IV. The two groups ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of lobaplatin in preparing medicines for treating malignant pleural mesothelioma. The lobaplatin is represented in dosage forms of lyophilized powder for injection, a small -volume injection or a large-volume injection, with an effective therapeutic dose of 30-60mg/m<2> body surface area. The lobaplatin and a preparation thereof are relatively strong in action of resisting the malignant pleural mesothelioma; and the lobaplatin and the preparation thereof are significant in therapeutic effect, low in toxicity and safe; therefore, a novel effective means is provided for the treatment of the malignant pleural mesothelioma and clinical application of the lobaplatin and the preparation thereof is widened.

Description

technical field [0001] The invention relates to a new application of lobaplatin, in particular to an application of lobaplatin in the preparation of medicines for treating malignant pleural mesothelioma. [0002] technical background [0003] In recent years, the morbidity and mortality of malignant tumors in my country have been increasing, surpassing cardiovascular disease and becoming a disease that seriously threatens the health and life of our people. [0004] Malignant pleural mesothelioma (MPM) is a malignant tumor derived from pleural mesothelial cells and is a primary tumor of the pleura. It is characterized by low incidence, difficulty in early diagnosis, local invasion, and poor prognosis. In recent decades, the incidence has gradually increased worldwide. According to histomorphological classification, MPM can be divided into three types: epithelial type, sarcomatoid (fibrous type) and mixed type, and the epithelial type is more common. The most common cause of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/282A61P35/00
CPCA61K31/555
Inventor 窦啟玲隋东虎张圣贵
Owner GUIZHOU YIBAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap